Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Daiichi Sankyo said on June 2 that it will initiate a clinical trial designed to look into the combination of its TROP2 directed DXd antibody drug conjugate (ADC) DS-1062 and US Merck’s immune checkpoint inhibitor Keytruda (pembrolizumab). The Japanese major…
To read the full story
Related Article
- Daiichi Sankyo, AstraZeneca to Launch PIII of DS-1062/Keytruda Combo
October 27, 2021
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





